SightfileU.S. market data from official filings

GT BIOPHARMA INC (GTBP)

Name: GT BIOPHARMA INC (GTBP) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000109657 · EDGAR filings · Updated 2026-07-02

GT BIOPHARMA INC (GTBP) has reported institutional ownership of 5.0%, with 41 institutional managers holding positions valued at $648.2K per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional ownership

5.0%

Institutional managers

Reported 13F value

$648.2K

Data flags

3 active

from SEC filings

Latest updates

2026-07-02 — Proxy statement (DEF 14A) filed
2026-06-18 — PRE 14A filed
2026-06-12 — Current report (8-K) filed
2026-05-22 — Current report (8-K) filed
2026-05-15 — Quarterly report (10-Q) filed
2026-05-13 — EFFECT filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GT BIOPHARMA INC has 41 institutional holders and institutional ownership of 5.0%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2026-05-22 (recurring since 2021-11-26) — source filing. The authoritative details are those stated in the filing itself.

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2020-03-27) — source filing. The authoritative details are those stated in the filing itself.

Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2026-03-02 (recurring since 2021-04-16) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Exicure Inc (XCUR) · P3 HEALTH PARTNERS INC (PIII) · Kiora Pharmaceuticals Inc (KPRX) · PHARMACYTE BIOTECH INC (PMCB) · INNOVATIVE EYEWEAR INC (LUCY) · INTERCURE LTD COM NEW (INCR)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.